BMS Divests Indonesian OTC Business, Continues Biopharma Consolidation
This article was originally published in The Tan Sheet
Executive Summary
Japanese firm Taisho Pharmaceutical will acquire nearly all shares of Bristol-Myers Squibb's Asian OTC subsidiary